Trial Profile
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Ranging, Phase 2b Study of the Safety and Efficacy of Continuous 48-Hour Intravenous Infusions of BMS-986231 in Hospitalized Patients With Heart Failure and Impaired Systolic Function
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jun 2022
Price :
$35
*
At a glance
- Drugs Cimlanod (Primary)
- Indications Decompensated heart failure
- Focus Therapeutic Use
- Acronyms STANDUP AHF
- Sponsors Bristol-Myers Squibb
- 26 Nov 2019 Status changed from recruiting to completed.
- 29 Jul 2019 Planned number of patients changed from 310 to 320.
- 06 Jun 2019 Trial design published in the European Journal of Heart Failure